Partial and full agonists of A1 adenosine receptors
Disclosed are novel compounds that are partial and full A 1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
1. A compound of the formula:
wherein:
R 1 is cycloalkyl optionally substituted with 1 to 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, SO 2 -aryl and —SO 2 -heteroaryl;
R 3 is a cycloalkyl, aryl; heteroaryl, or heterocyclyl moiety that may be optionally substituted with 1 to 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl,—SO-heteroaryl, —SO 2 -alkyl, SO 2 -aryl and —SO 2 -heteroaryl,
R 4 and R 5 are independently hydrogen or acyl; and
X is a covalent bond or alkylene optionally substituted with halogen or lower alkyl.
2. The compound of claim 1 , wherein R 3 is optionally substituted aryl or optionally substituted heteroaryl.
3. The compound of claim 2 , wherein R 4 and R 5 are hydrogen.
4. The compound of claim 3 , wherein R 3 is optionally substituted aryl.
5. The compound of claim 4 , wherein R 1 is optionally substituted cycloalkyl, X is a covalent bond, and R 3 is optionally substituted phenyl.
6. The compound of claim 5 , wherein R 1 is optionally substituted cyclopentyl and R 3 is phenyl substituted with at least one moiety selected from the group consisting of halogen and lower alkyl.
7. The compound of claim 6 , wherein R 1 is 2-hydroxycyclopentyl.
8. The compound of claim 7 , wherein R 3 is 2-chloro-6-methylphenyl, namely 2- {6-[((1R,2R)-2-hydroxycyclopentyl)amino]purin-9-yl}(4S,5S,2R,3R)-5-[(2-chloro-6methylphenylthio)methyl]oxolane-3,4-diol.
9. The compound of claim 7 , wherein R 3 is 2,6-dimethylphenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclopentyl)amino]purin-9-yl}(4S,5S,2R,3R)-5-[2,6-dimethylphenylthio)methyl]oxolane-3,4-diol.
10. The compound of claim 7 , wherein R 3 is 2-methylphenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclopentyl)amino]purin-9-yl}(4S,5S,2R,3R)-5-[(2-methylphenylthio)methyl]oxolane-3,4-diol.
11. The compound of claim 7 , wherein R 3 is 3-fluorophenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclopentyl)amino]purin-9-yl}(4S,5S,2R,3R)-5[(3-fluorophenylthio)methyl]oxolane-3,4-diol.
12. The compound of claim 7 , wherein R 3 is 2-chlorophenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclopentyl)amino]purin-9-yl}(4S,5S,2R,3R)-5-[(2-chlorophenylthio)methyl]oxolane-3,4-diol.
13. The compound of claim 7 , wherein R 3 is 2,4-difluorophenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclopentyl)amino]purin-9-yl}(4S,5S,2R,3R)-5-[(2,4-difluorophenylthio)methyl]oxolane-3,4-diol.
14. The compound of claim 7 , wherein R 3 is 4-chlorophenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclopentyl)amino]purin-9-yl}(4S,5S,2R,3R)-5-[(4-chlorophenylthio)methyl]oxolane-3,4-diol.
15. The compound of claim 7 , wherein R 3 is 4-fluorophenyl, namely 2-{6-[((1R,2R)-2-hydroxycyclopentyl)amino]purin-9-yl}(4S,5S,2R,3R)-5-[(4-fluorophenylthio)methyl]oxolane-3,4-diol.
16. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective adenosine A 1 receptor agonizing amount of a compound of Formula I
wherein:
R 1 is cycloalkyl optionally substituted with 1 to 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl,—SO-heteroaryl, —SO 2 -alkyl, SO 2 aryl and —SO 2 -heteroaryl;
R 3 is a cycloalkyl, aryl; heteroaryl, or heterocyclyl moiety that may be optionally substituted with 1 to 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclythio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, SO 2 -aryl and —SO 2 -heteroaryl,
R 4 and R 5 are independently hydrogen or acyl; and
X is a covalent bond or alkylene optionally substituted wit halogen or lower alkyl.